Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the
development and sale of broadly enabling, pressure-based technology and
products to the worldwide life sciences and other industries, today announced
the publication of two scientific journal articles led by independent teams of
scientists in China and Australia. Per the update, the articles reported
excellent results with PBI’s Pressure Cycling Technology (“PCT”) platform in
processing preserved formalin-fixed paraffin-embedded (“FFPE”) and fresh frozen
biopsy tissue samples for discovery and elucidation of cancer biomarkers, as
well as potential use in clinical diagnostics based upon these markers. “It is
estimated (Nature volume 448, pages 959–962, 23 August 2007) that well over one
billion archival FFPE tissue samples exist in pathology and other laboratories
worldwide. We believe there are millions of new FFPE tissue samples processed
and stored each year,” Pressure BioSciences President and CEO Richard T. Schumacher
said in the news release. “These samples offer the promise of unveiling
invaluable information that can lead to the development of new treatments,
cures, and preventive measures for cancer and many other diseases. However, up
to now, it has been very difficult to extract this information from
biomolecules in FFPE samples.”
To view the full press release, visit http://ibn.fm/QhPt0
About Pressure BioSciences Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the
development and sale of innovative, broadly enabling, pressure-based solutions
for the worldwide life sciences industry. The company’s products are based on
the unique properties of both constant (i.e., static) and alternating (i.e.,
pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented
enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to safely and reproducibly
control bio-molecular interactions (e.g., cell lysis, biomolecule extraction).
PBIO’s primary focus is in the development of PCT-based products for biomarker
and target discovery, drug design and development, biotherapeutics
characterization and quality control, soil & plant biology, forensics, and
counter-bioterror applications. Additionally, major new market opportunities
have emerged in the use of its pressure-based technologies in the following
areas: (1) the use of its recently acquired PreEMT technology from BaroFold,
Inc. to allow entry into the biologics contract research services sector, and
(2) the use of its recently-patented, scalable, high-efficiency, pressure-based
Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of
otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher
quality, homogenized, extended shelf-life or room temperature stable low-acid
liquid foods that cannot be effectively preserved using existing non-thermal
technologies. For more information, visit the company’s website at www.PressureBiosciences.com
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
